There is some precedent for this, as ACBD3 was found to be suppressed by ER signaling but is highest in ER+ cell lines, suggesting that repressors of ACBD3 may be reprogrammed in breast cancer. This evidence concerns the gene ACBD3 and breast carcinoma.